Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Figure 3 | BMC Cancer

Figure 3

From: Breast and prostate cancer patients differ significantly in their serum Thymidine kinase 1 (TK1) specific activities compared with those hematological malignancies and blood donors: implications of using serum TK1 as a biomarker

Figure 3

TK1 activity and protein levels in breast cancer patients and blood donors. (A) STK1 activity distributions in sera from blood donors (•) and patients with breast cancer (■). (B) STK1 protein levels in sera from blood donors (•) and patients with breast cancer (■). (C) Comparison of STK1 activities in sera from blood donors (•) and early-stage (TiS + T1; ■) and late-stage (T2 + T3; ▲) breast cancer patients. (D) Comparison of STK1 protein levels in sera from blood donors (•) and early-stage (TiS + T1; ■) and late stage (T2 + T3; ▲) breast cancer patients. (E) Comparison of STK1 activities in blood donors (•) and non-invasive (DCIS; ■) and invasive (ID + ID/L; ▲) breast cancer patients. (F) Comparison of STK1 protein levels in blood donors (•) and non-invasive (DCIS; ■) and invasive (ID + ID/L) breast cancer patients (▲). The error bars denote standard deviations (SDs). (G) Receiver operating characteristic (ROC) curve of STK1 activity in serum samples from breast cancer patients and from blood donors. (H) ROC curve analysis of STK1 protein levels in sera from blood donors and breast cancer patients.

Back to article page